Genomic landscape and clinical utility of Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program-Reference-Cited by-同舟云学术

Genomic landscape and clinical utility of Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program

Published:2021-12-03 Issue: Volume: Page:candisc.1064.2021
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Park Kyong Hwa^ORCID,Choi Jung Yoon^ORCID,Lim Ah-reum,Kim Ju Won,Choi Yoon Ji,Lee Soohyeon,Sung Jae Sook,Chung Hee-Joon,Jang Byunghyun,Yoon Dayoung,Kim Sukwon^ORCID,Sa Jason K^ORCID,Kim Yeul Hong^ORCID

Funder

National Research Foundation of Korea

Ministry of Health and Welfare

Korea Health Industry Development Institute

MOTIE | Korea Evaluation Institute of Industrial Technology

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17);ESMO Open;2024-09

2. The prognostic and immune significance of SLAMF9 in pan-cancer and validation of its role in colorectal cancer;Scientific Reports;2024-08-02

3. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

4. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12);OncoImmunology;2024-06-24

5. Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer;BMC Cancer;2024-04-20